At the 61st ASH Annual Meeting & Exposition, Abdulraheem Yacoub, University of Kansas Medical Center, discusses his presentation: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis.
Questions
1. What are the most exciting recent advances in the treatment of polycythemia vera and myelofibrosis? (0:05)
2. What role is next generation sequence technology likely to play in the future management of myeloproliferative neoplasms? (0:51)
3. How has increased understanding of these diseases helped select the most appropriate treatment strategy for an individual? (2:13)
4. What is the best treatment strategy for patients who experience symptomatic disease progression? (3:46)
5. What progress has been made in terms of combined therapy for the treatment of polycythemia vera and myelofibrosis? (6:30)
Abdulraheem Yacoub has been a consultant for Incyte, Novartis and Agios.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
